Detailed solution introduction
The MTAM-HFA is based on the US National Cancer Institute (NCI) developed technique known as the Hollow Fiber Assay (HFA). We introduce a new component known as the Microtube Array Membrane (MTAM) which consists of a whole host of beneficial microstructures which are patented with multiple patents both in the US and Taiwan. The combination of tumor cells (primary/cell line) which can be solid or non-solid, which are then siphoned into the lumens of the MTAMs; fused and subcutaneously implanted into the backs of Balb/C mice. Anti-cancer drugs (small molecule, protein, immunotherapy, cell therapy*) are administered accordingly and the entire test can be completed within 14 days. ,
Primarily, our solutions can be divided into 3 major categories each targeting a very different market segment in the personalization of cancer treatment and anti-cancer drug development pipeline.
With MTAM/Select (personalized medicine), oncologist/patients can choose to test their tumor samples against several probable anti-cancer drugs. Primary tumor samples would be encapsulated within our MTAM and subcutaneously implanted into Balb/c mice and anti-cancer drugs would be administered. Results are based on the well-established MTT assay and made available within a clinical practical time frame of 10-20 days; enabling oncologist to administer the correct treatment on the very first time and reducing any potential side effects associated with multiple ineffective anti-cancer treatments.
MTAM/Trial (Pre-clinical patient segment selection) empowers drug developer by pre-identification of susceptible patients segments for their respective lead drug candidate before any clinical trials are conducted. With this empowerment, drug developers can selectively conduct targeted clinical trial against a particular susceptible patient segment, thereby significantly increasing the odds of successfully passing the clinical trials (especially Phase 2 of the clinical trial-the efficacy stage).
MTAM/Select (Pre-clinical anti-cancer drug compound screening), originally develop to assist drug developers as a form of high-throughput, rapid and reliable screening solution for the vast quantity of candidate compounds, which are often encountered during the pre-clinical development phase. Combined with unprecedented translatability and cost savings; significantly benefits a broad range of drug developers from academia based to pharmaceutical titans.
As our solutions share a common technology basis, our solutions confer value/benefits to users and patients ranging from superior rapidness while maintaining a high standard of accuracy; making personalized cancer treatment available to everyone through the reduction of cost; the capability to screen a large variety of cancer types ranging from solid, non-solid to rare cancers; and the ability to screen multiple different drug classes ranging from small molecule, protein to the recent area of focus-immunotherapy.
We are currently undergoing mutiple clinical trials with seveal local hospitals. Breast cancer and colon cancer trials demonstrate high clinical correlation between the MTAM-HFA screening utcome and the clinical outcome of patients. In the field of immunotherapy screening, we have sucessfully demonstrated excellent clinical outcome of recurrent lung cancer patient using our prescreened drug combination of Nivolumab (anti PD-1) & Paclitaxel. Future indications of use remains to be seen.